Loading...
Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy
PIK3CA, which encodes the catalytic p110α subunit of phosphatidylinositol 3-kinase α, is the most frequently mutated oncogene in human cancers. Targeting mutant p110α holds great promise for cancer therapy. However, it is challenging to develop p110α isoform-specific inhibitors. Most p110α mutations...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2013
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3916152/ https://ncbi.nlm.nih.gov/pubmed/24178578 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0192623313506794 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|